Immunotherapy: Biomarkers of immunotherapy-induced colitis

Nature Reviews Cancer 16, 129 (2016). doi:10.1038/nrc.2016.22 Author: Sarah Seton-Rogers Despite the therapeutic efficacy of immune checkpoint inhibitors against some tumours, immune-related side effects remain a large concern. Dubin et al. show in a prospective study of patients with melanoma that new-onset colitis associated with the cytotoxic T lymphocyte-associated antigen 4 (CTLA4) inhibitor ipilimumab

http://feeds.nature.com/~r/nrc/rss/current/~3/Tj0dJDiy3_M/nrc.2016.22

Source: Nature Reviews Cancer - February 25, 2016 Category: Cancer & Oncology Authors: Sarah Seton-Rogers Tags: Research Highlight Source Type: research